Plozasiran vs RN0361

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertriglyceridemia

Shared mechanism: APOC3 · full Hypertriglyceridemia pipeline

Plozasiran · Redemplo

Marketed by Arrowhead Pharmaceuticals and partners

Phase 3 in HypertriglyceridemiaRNAi (siRNA)
Partial signal

NCT06347003 · Phase 3 · completed

This was a randomized, quadruple-masked Phase 3 trial with 446 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-22. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: July 2028 · NCT06822790 (registry estimate)

Reported efficacy

Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo (Baseline, Month 12): Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22). (met)

Result source: NCT06347003

RN0361

Developed by Rona Therapeutics and partners

Phase 1/2 in HypertriglyceridemiaRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Hypertriglyceridemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

RN0361: no structured comparison results are available for Hypertriglyceridemia.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Plozasiran

Fasting TG -74.2% (n=55) vs -17.2% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 65 more results
-77.6% (n=57) vs 7.2% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-72.8% (n=57) vs -0.7% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.3% (n=57) vs -7.3% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-76.3% (n=57) vs -2.9% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-75.6% (n=57) vs 2.4% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-74.2% (n=57) vs -17.2% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.8% (n=57) vs -11.7% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.6% (n=57) vs -7.6% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.4% (n=57) vs -6.6% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-64.1% (n=62) vs -1.7% (n=81) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-45.9% (n=61) vs -1.7% (n=81) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-66.4% (n=64) vs -0.5% (n=85) placebo @ 4wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-62.5% (n=65) vs -0.5% (n=85) placebo @ 4wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-65% (n=64) vs -0.4% (n=85) placebo @ 8wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-59.7% (n=65) vs -0.4% (n=85) placebo @ 8wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-57.9% (n=64) vs -0.1% (n=85) placebo @ 12wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-51.7% (n=65) vs -0.1% (n=85) placebo @ 12wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-68.3% (n=64) vs -1.8% (n=85) placebo @ 16wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-50.6% (n=65) vs -1.8% (n=85) placebo @ 16wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-64.7% (n=64) vs 1.2% (n=85) placebo @ 20wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-49.1% (n=65) vs 1.2% (n=85) placebo @ 20wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-64.1% (n=64) vs -1.7% (n=85) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-45.9% (n=65) vs -1.7% (n=85) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-61.7% (n=64) vs 3.5% (n=85) placebo @ 28wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-63.4% (n=65) vs 3.5% (n=85) placebo @ 28wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-54.9% (n=64) vs 6.1% (n=85) placebo @ 36wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-60.1% (n=65) vs 6.1% (n=85) placebo @ 36wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-70.2% (n=54) vs -17.2% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.5% (n=55) vs 7.2% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.2% (n=55) vs -0.7% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-64.9% (n=55) vs -7.3% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-80.1% (n=55) vs -2.9% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-75.3% (n=55) vs 2.4% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.2% (n=55) vs -17.2% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.3% (n=55) vs -11.7% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-64% (n=55) vs -7.6% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-58% (n=55) vs -6.6% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-57.7% (n=63) vs -1.7% (n=81) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-61.5% (n=67) vs -0.5% (n=85) placebo @ 4wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-58.1% (n=67) vs -0.4% (n=85) placebo @ 8wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-53.6% (n=67) vs -0.1% (n=85) placebo @ 12wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-62% (n=67) vs -1.8% (n=85) placebo @ 16wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-62% (n=67) vs 1.2% (n=85) placebo @ 20wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-57.7% (n=67) vs -1.7% (n=85) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-55.7% (n=67) vs 3.5% (n=85) placebo @ 28wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-51.5% (n=67) vs 6.1% (n=85) placebo @ 36wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-66% (n=50) vs -17.2% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-63.3% (n=54) vs 7.2% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-54% (n=54) vs -0.7% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.9% (n=54) vs -7.3% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.5% (n=54) vs -2.9% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-67.7% (n=54) vs 2.4% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-66% (n=54) vs -17.2% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-60% (n=54) vs -11.7% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-37.7% (n=54) vs -7.6% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-31.4% (n=54) vs -6.6% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-51.5% (n=61) vs -1.7% (n=81) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-51.4% (n=64) vs -0.5% (n=85) placebo @ 4wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-48.6% (n=64) vs -0.4% (n=85) placebo @ 8wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-43.8% (n=64) vs -0.1% (n=85) placebo @ 12wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-58% (n=64) vs -1.8% (n=85) placebo @ 16wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-54.6% (n=64) vs 1.2% (n=85) placebo @ 20wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-51.5% (n=64) vs -1.7% (n=85) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-46.2% (n=64) vs 3.5% (n=85) placebo @ 28wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-44.7% (n=64) vs 6.1% (n=85) placebo @ 36wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Apo C3 -79.4% (n=55) vs 114.2% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 92 more results
-84.6% (n=57) vs 209.3% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.9% (n=57) vs 146.3% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.2% (n=57) vs 122.2% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-87.1% (n=57) vs 134.4% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84% (n=57) vs 118.8% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.4% (n=57) vs 114.2% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-74.7% (n=57) vs 140.2% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.9% (n=57) vs 152% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48.3% (n=57) vs 135.8% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-83.2% (n=57) vs 7% (n=57) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.7% (n=57) vs 4.7% (n=57) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-72.2% (n=57) vs 0% (n=57) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-86.3% (n=57) vs 2.8% (n=57) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-82.6% (n=57) vs 7.8% (n=57) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.2% (n=57) vs -0.8% (n=57) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.2% (n=57) vs -2.2% (n=57) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-58.3% (n=57) vs 0.2% (n=57) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-46.8% (n=57) vs 5.6% (n=57) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-65.7% (n=62) vs 23.9% (n=79) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-57.9% (n=61) vs 23.9% (n=79) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-78.4% (n=64) vs 19.3% (n=84) placebo @ 4wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-82.7% (n=65) vs 19.3% (n=84) placebo @ 4wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-71.8% (n=64) vs 19% (n=84) placebo @ 8wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-78.1% (n=65) vs 19% (n=84) placebo @ 8wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-59.2% (n=64) vs 20.3% (n=84) placebo @ 12wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-71.5% (n=65) vs 20.3% (n=84) placebo @ 12wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-78.9% (n=64) vs 10.9% (n=84) placebo @ 16wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-67.7% (n=65) vs 10.9% (n=84) placebo @ 16wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-69.3% (n=64) vs 21.8% (n=84) placebo @ 20wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-62.6% (n=65) vs 21.8% (n=84) placebo @ 20wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-65.7% (n=64) vs 23.9% (n=84) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-57.9% (n=65) vs 23.9% (n=84) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-53.3% (n=64) vs 35.6% (n=84) placebo @ 28wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-82.5% (n=65) vs 35.6% (n=84) placebo @ 28wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-34.5% (n=64) vs 30.6% (n=84) placebo @ 36wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-75.8% (n=65) vs 30.6% (n=84) placebo @ 36wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-73.7% (n=54) vs 114.2% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84.4% (n=55) vs 209.3% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.8% (n=55) vs 146.3% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.8% (n=55) vs 122.2% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-86.4% (n=55) vs 134.4% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-81.2% (n=55) vs 118.8% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.7% (n=55) vs 114.2% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.9% (n=55) vs 140.2% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-60.9% (n=55) vs 152% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-49.6% (n=55) vs 135.8% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-82.9% (n=55) vs 7% (n=57) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-77.2% (n=55) vs 4.7% (n=57) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.3% (n=55) vs 0% (n=57) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84.9% (n=55) vs 2.8% (n=57) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.7% (n=55) vs 7.8% (n=57) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-72.1% (n=55) vs -0.8% (n=57) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.2% (n=55) vs -2.2% (n=57) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.1% (n=55) vs 0.2% (n=57) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48% (n=55) vs 5.6% (n=57) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-44.3% (n=63) vs 23.9% (n=79) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-69.7% (n=67) vs 19.3% (n=84) placebo @ 4wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-61.9% (n=67) vs 19% (n=84) placebo @ 8wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-18.9% (n=67) vs 20.3% (n=84) placebo @ 12wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-63.8% (n=67) vs 10.9% (n=84) placebo @ 16wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-63.3% (n=67) vs 21.8% (n=84) placebo @ 20wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-44.3% (n=67) vs 23.9% (n=84) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-32.8% (n=67) vs 35.6% (n=84) placebo @ 28wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-24.9% (n=67) vs 30.6% (n=84) placebo @ 36wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-69.6% (n=49) vs 114.2% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-67.3% (n=54) vs 209.3% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.8% (n=54) vs 146.3% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-55.5% (n=54) vs 122.2% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-77.1% (n=54) vs 134.4% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.7% (n=54) vs 118.8% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-69.6% (n=54) vs 114.2% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-64.4% (n=54) vs 140.2% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-50.2% (n=54) vs 152% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.5% (n=54) vs 135.8% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-65.1% (n=53) vs 7% (n=57) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-57.3% (n=53) vs 4.7% (n=57) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.2% (n=53) vs 0% (n=57) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-74.8% (n=53) vs 2.8% (n=57) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-69.9% (n=53) vs 7.8% (n=57) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-68.1% (n=53) vs -0.8% (n=57) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-63% (n=53) vs -2.2% (n=57) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48.5% (n=53) vs 0.2% (n=57) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-33.7% (n=53) vs 5.6% (n=57) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-58.9% (n=59) vs 23.9% (n=79) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-60.7% (n=63) vs 19.3% (n=84) placebo @ 4wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-57.3% (n=63) vs 19% (n=84) placebo @ 8wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-48.7% (n=63) vs 20.3% (n=84) placebo @ 12wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-69.9% (n=63) vs 10.9% (n=84) placebo @ 16wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-64% (n=63) vs 21.8% (n=84) placebo @ 20wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-58.9% (n=63) vs 23.9% (n=84) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-51.7% (n=63) vs 35.6% (n=84) placebo @ 28wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-46.3% (n=63) vs 30.6% (n=84) placebo @ 36wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Non-HDL-C -21.7% (n=55) vs -1.5% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 65 more results
-26.1% (n=57) vs 6.3% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-20.7% (n=57) vs 4.5% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-22.3% (n=57) vs 1.4% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-23.7% (n=57) vs 1.8% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-22.9% (n=57) vs 5.7% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-21.7% (n=57) vs -1.5% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-24% (n=57) vs -2.3% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-13.1% (n=57) vs -0.3% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-13.5% (n=57) vs 0.5% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-26.9% (n=62) vs -2.7% (n=81) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-10.3% (n=61) vs -2.7% (n=81) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-26.3% (n=64) vs -1.2% (n=85) placebo @ 4wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-19.6% (n=65) vs -1.2% (n=85) placebo @ 4wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-27.8% (n=64) vs -1% (n=85) placebo @ 8wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-16.2% (n=65) vs -1% (n=85) placebo @ 8wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-21.9% (n=64) vs -0.4% (n=85) placebo @ 12wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-16% (n=65) vs -0.4% (n=85) placebo @ 12wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-28.5% (n=64) vs -1.4% (n=85) placebo @ 16wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-15.5% (n=65) vs -1.4% (n=85) placebo @ 16wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-27.3% (n=64) vs -1.9% (n=85) placebo @ 20wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-11.7% (n=65) vs -1.9% (n=85) placebo @ 20wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-26.9% (n=64) vs -2.7% (n=85) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-10.3% (n=65) vs -2.7% (n=85) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-25.6% (n=64) vs 0.4% (n=85) placebo @ 28wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-20.5% (n=65) vs 0.4% (n=85) placebo @ 28wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-23.4% (n=64) vs 0% (n=85) placebo @ 36wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-17.3% (n=65) vs 0% (n=85) placebo @ 36wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-28.4% (n=54) vs -1.5% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.7% (n=55) vs 6.3% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-30.7% (n=55) vs 4.5% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-30% (n=55) vs 1.4% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-37.8% (n=55) vs 1.8% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.6% (n=55) vs 5.7% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-28.4% (n=55) vs -1.5% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-31.3% (n=55) vs -2.3% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-23.8% (n=55) vs -0.3% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-23% (n=55) vs 0.5% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-20.1% (n=63) vs -2.7% (n=81) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-23.3% (n=67) vs -1.2% (n=85) placebo @ 4wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-22.4% (n=67) vs -1% (n=85) placebo @ 8wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-19.4% (n=67) vs -0.4% (n=85) placebo @ 12wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-23.8% (n=67) vs -1.4% (n=85) placebo @ 16wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-21.5% (n=67) vs -1.9% (n=85) placebo @ 20wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-20.1% (n=67) vs -2.7% (n=85) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-17.7% (n=67) vs 0.4% (n=85) placebo @ 28wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-17.1% (n=67) vs 0% (n=85) placebo @ 36wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-29.4% (n=49) vs -1.5% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-27% (n=54) vs 6.3% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-19.7% (n=54) vs 4.5% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-19.3% (n=54) vs 1.4% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-27.9% (n=54) vs 1.8% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-26.7% (n=54) vs 5.7% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-29.4% (n=54) vs -1.5% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-27.4% (n=54) vs -2.3% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-19.2% (n=54) vs -0.3% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-10% (n=54) vs 0.5% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-19.3% (n=61) vs -2.7% (n=81) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-17.3% (n=64) vs -1.2% (n=85) placebo @ 4wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-18.2% (n=64) vs -1% (n=85) placebo @ 8wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-15.5% (n=64) vs -0.4% (n=85) placebo @ 12wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-21.2% (n=64) vs -1.4% (n=85) placebo @ 16wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-20.9% (n=64) vs -1.9% (n=85) placebo @ 20wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-19.3% (n=64) vs -2.7% (n=85) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-17.1% (n=64) vs 0.4% (n=85) placebo @ 28wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-17.1% (n=64) vs 0% (n=85) placebo @ 36wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
HDL-C 67.6% (n=55) vs 10.6% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 65 more results
88.1% (n=57) vs 4.3% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
67.7% (n=57) vs 6.2% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
62.5% (n=57) vs 11.3% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
82.6% (n=57) vs 5.7% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
81.2% (n=57) vs 8.8% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
67.6% (n=57) vs 10.6% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
68% (n=57) vs 10.2% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
47.2% (n=57) vs 11.7% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
37.8% (n=57) vs 6.1% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
50.5% (n=62) vs 4.7% (n=81) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
32.8% (n=61) vs 4.7% (n=81) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
55.4% (n=64) vs 3.6% (n=85) placebo @ 4wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
55.5% (n=65) vs 3.6% (n=85) placebo @ 4wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
54.3% (n=64) vs 2% (n=85) placebo @ 8wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
52.8% (n=65) vs 2% (n=85) placebo @ 8wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
49% (n=64) vs 2.5% (n=85) placebo @ 12wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
45.1% (n=65) vs 2.5% (n=85) placebo @ 12wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
64.2% (n=64) vs 3.2% (n=85) placebo @ 16wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
41.6% (n=65) vs 3.2% (n=85) placebo @ 16wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
58.2% (n=64) vs 2.8% (n=85) placebo @ 20wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
40.3% (n=65) vs 2.8% (n=85) placebo @ 20wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
50.5% (n=64) vs 4.7% (n=85) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
32.8% (n=65) vs 4.7% (n=85) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
49.5% (n=64) vs 2.1% (n=85) placebo @ 28wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
54% (n=65) vs 2.1% (n=85) placebo @ 28wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
43.1% (n=64) vs 1.6% (n=85) placebo @ 36wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
49.7% (n=65) vs 1.6% (n=85) placebo @ 36wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
62.8% (n=54) vs 10.6% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
76.2% (n=55) vs 4.3% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
73.5% (n=55) vs 6.2% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
60.2% (n=55) vs 11.3% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
87.1% (n=55) vs 5.7% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
78.7% (n=55) vs 8.8% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
62.8% (n=55) vs 10.6% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
67.2% (n=55) vs 10.2% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
51.1% (n=55) vs 11.7% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
32.4% (n=55) vs 6.1% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
46.8% (n=63) vs 4.7% (n=81) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
48.3% (n=67) vs 3.6% (n=85) placebo @ 4wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
46.4% (n=67) vs 2% (n=85) placebo @ 8wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
40.1% (n=67) vs 2.5% (n=85) placebo @ 12wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
56.4% (n=67) vs 3.2% (n=85) placebo @ 16wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
50.6% (n=67) vs 2.8% (n=85) placebo @ 20wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
46.8% (n=67) vs 4.7% (n=85) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
45.3% (n=67) vs 2.1% (n=85) placebo @ 28wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
37% (n=67) vs 1.6% (n=85) placebo @ 36wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
54.2% (n=49) vs 10.6% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
53.4% (n=54) vs 4.3% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
45.4% (n=54) vs 6.2% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
39.9% (n=54) vs 11.3% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
66.2% (n=54) vs 5.7% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
61.2% (n=54) vs 8.8% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
54.2% (n=54) vs 10.6% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
48.2% (n=54) vs 10.2% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
34.5% (n=54) vs 11.7% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
23.5% (n=54) vs 6.1% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
37.9% (n=61) vs 4.7% (n=81) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
39.3% (n=64) vs 3.6% (n=85) placebo @ 4wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
32.1% (n=64) vs 2% (n=85) placebo @ 8wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
31.4% (n=64) vs 2.5% (n=85) placebo @ 12wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
45.8% (n=64) vs 3.2% (n=85) placebo @ 16wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
45% (n=64) vs 2.8% (n=85) placebo @ 20wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
37.9% (n=64) vs 4.7% (n=85) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
35.8% (n=64) vs 2.1% (n=85) placebo @ 28wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
30.8% (n=64) vs 1.6% (n=85) placebo @ 36wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Apo B 0.7% (n=55) vs 8% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 65 more results
-1.9% (n=57) vs 16.2% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
1.5% (n=57) vs 16% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-1.3% (n=57) vs 4.2% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.6% (n=57) vs 5.3% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
4.4% (n=57) vs 1.6% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
0.7% (n=57) vs 8% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
0.6% (n=57) vs 3.9% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
8.5% (n=57) vs 8.9% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
2.4% (n=57) vs 5.7% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-18.3% (n=62) vs 0.8% (n=79) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-5.7% (n=61) vs 0.8% (n=79) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-18.5% (n=64) vs -1.3% (n=84) placebo @ 4wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-13.5% (n=65) vs -1.3% (n=84) placebo @ 4wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-20.3% (n=64) vs -0.5% (n=84) placebo @ 8wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-10.9% (n=65) vs -0.5% (n=84) placebo @ 8wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-14.8% (n=64) vs 0.9% (n=84) placebo @ 12wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-10.8% (n=65) vs 0.9% (n=84) placebo @ 12wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-20.6% (n=64) vs 0.2% (n=84) placebo @ 16wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-9.4% (n=65) vs 0.2% (n=84) placebo @ 16wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-19.3% (n=64) vs 0.5% (n=84) placebo @ 20wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-7.3% (n=65) vs 0.5% (n=84) placebo @ 20wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-18.3% (n=64) vs 0.8% (n=84) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-5.7% (n=65) vs 0.8% (n=84) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-16.3% (n=64) vs 5.1% (n=84) placebo @ 28wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-12.1% (n=65) vs 5.1% (n=84) placebo @ 28wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-15.4% (n=64) vs 3.7% (n=84) placebo @ 36wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-9.9% (n=65) vs 3.7% (n=84) placebo @ 36wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-5.3% (n=54) vs 8% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-9% (n=55) vs 16.2% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-7.2% (n=55) vs 16% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-11.2% (n=55) vs 4.2% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-13.1% (n=55) vs 5.3% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-10.3% (n=55) vs 1.6% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-5.3% (n=55) vs 8% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-6% (n=55) vs 3.9% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
2.5% (n=55) vs 8.9% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.2% (n=55) vs 5.7% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-12.2% (n=63) vs 0.8% (n=79) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-15.5% (n=67) vs -1.3% (n=84) placebo @ 4wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-15.5% (n=67) vs -0.5% (n=84) placebo @ 8wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-14.3% (n=67) vs 0.9% (n=84) placebo @ 12wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-17.2% (n=67) vs 0.2% (n=84) placebo @ 16wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-14.3% (n=67) vs 0.5% (n=84) placebo @ 20wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-12.2% (n=67) vs 0.8% (n=84) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-10% (n=67) vs 5.1% (n=84) placebo @ 28wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-9.3% (n=67) vs 3.7% (n=84) placebo @ 36wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
6% (n=49) vs 8% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-2.3% (n=54) vs 16.2% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.8% (n=54) vs 16% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
0.5% (n=54) vs 4.2% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.8% (n=54) vs 5.3% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.7% (n=54) vs 1.6% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
6% (n=54) vs 8% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-1.3% (n=54) vs 3.9% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.4% (n=54) vs 8.9% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
6.4% (n=54) vs 5.7% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-9.5% (n=59) vs 0.8% (n=79) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-10.3% (n=63) vs -1.3% (n=84) placebo @ 4wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-11% (n=63) vs -0.5% (n=84) placebo @ 8wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-8.5% (n=63) vs 0.9% (n=84) placebo @ 12wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-12.8% (n=63) vs 0.2% (n=84) placebo @ 16wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-13% (n=63) vs 0.5% (n=84) placebo @ 20wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-9.5% (n=63) vs 0.8% (n=84) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-9% (n=63) vs 5.1% (n=84) placebo @ 28wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-7.8% (n=63) vs 3.7% (n=84) placebo @ 36wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Fasting TG -50.2% (n=64) vs 1.7% (n=85) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
-55% (n=65) vs 1.7% (n=85) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-42.8% (n=67) vs 1.7% (n=85) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-33.2% (n=64) vs 1.7% (n=85) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
Apo C3 -17.4% (n=64) vs 27.3% (n=84) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
-64.8% (n=65) vs 27.3% (n=84) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-13.9% (n=67) vs 27.3% (n=84) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-31.2% (n=63) vs 27.3% (n=84) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
Non-HDL-C -21.8% (n=64) vs 1.7% (n=85) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
-20% (n=65) vs 1.7% (n=85) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-12.1% (n=67) vs 1.7% (n=85) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-12.1% (n=64) vs 1.7% (n=85) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
HDL-C 34.3% (n=64) vs 4.5% (n=85) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
44.5% (n=65) vs 4.5% (n=85) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
30.5% (n=67) vs 4.5% (n=85) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
25.4% (n=64) vs 4.5% (n=85) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
Apo B -12.2% (n=64) vs 3.3% (n=84) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
-11.9% (n=65) vs 3.3% (n=84) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-6.4% (n=67) vs 3.3% (n=84) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-4.7% (n=63) vs 3.3% (n=84) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
Available safety results

Plozasiran

Dropout rate
7%50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
show 6 more results
5.5%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
9.1%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
7.6%50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
7.6%50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
4.5%25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
10.4%10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.8%50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
show 6 more results
0%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
1.8%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
0%50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
1.5%50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
0%25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
1.5%10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Serious AEs
12.5%50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
show 6 more results
3.6%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
7.4%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
10.6%50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
7.6%50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
7.5%25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
3%10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
50 mg
covid-19 16.1% (placebo 14.8%)
upper respiratory tract infection 12.5% (placebo 6.6%)
type 2 diabetes mellitus 10.7% (placebo 4.9%)
NCT04720534 · Phase 2 · registry result, not featured evidence
show 6 more results
25 mg
covid-19 16.4% (placebo 14.8%)
headache 10.9% (placebo 4.9%)
sinusitis 7.3% (placebo 0%)
NCT04720534 · Phase 2 · registry result, not featured evidence
10 mg
covid-19 20.4% (placebo 14.8%)
headache 14.8% (placebo 4.9%)
urinary tract infection 11.1% (placebo 9.8%)
NCT04720534 · Phase 2 · registry result, not featured evidence
50 mg Q12W
covid-19 13.6% (placebo 13.8%)
type 2 diabetes mellitus 12.1% (placebo 4.6%)
urinary tract infection 9.1% (placebo 8%)
NCT04998201 · Phase 2 · registry result, not featured evidence
50 mg Q24W
type 2 diabetes mellitus 16.7% (placebo 4.6%)
upper respiratory tract infection 13.6% (placebo 8%)
covid-19 9.1% (placebo 13.8%)
NCT04998201 · Phase 2 · registry result, not featured evidence
25 mg Q12W
covid-19 16.4% (placebo 13.8%)
upper respiratory tract infection 10.4% (placebo 8%)
urinary tract infection 9% (placebo 8%)
NCT04998201 · Phase 2 · registry result, not featured evidence
10 mg Q12W
covid-19 11.9% (placebo 13.8%)
type 2 diabetes mellitus 7.5% (placebo 4.6%)
bronchitis 6% (placebo 1.1%)
NCT04998201 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Plozasiran's landscape · RN0361's landscape